Abstract Next Generation Sequencing (NGS) has dramatically improved the flexibility and
outcomes of cancer research and clinical trials, providing highly sensitive and accurate high …

The life of every organism is dependent on the fine-tuned mechanisms of protein synthesis
and breakdown. The degradation of most intracellular proteins is performed by the ubiquitin …

We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-
house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study …

Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …

Abstract Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that
sustains proteostasis network under a large variety of physiopathological conditions. Its …

Decades of research into the molecular mechanisms of cancer and the development of
novel therapeutics have yielded a number of remarkable successes. However, our ability to …

Emergence of resistance is a major factor limiting the efficacy of molecularly targeted
anticancer drugs. Understanding the specific mutations, or other genetic or cellular changes …

Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …

Simple Summary Multiple myeloma (MM) is a still uncurable tumor of mainly elderly patients
originating from the terminally differentiated B cells. Introduction to the treatment of MM …

Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …